BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI

Main Article Content

Alice B Gottlieb
Bruce Strober
Diamant Thaçi
Kenneth Gordon
Sundeep Kundu
Renata Kisa
Lan Wei
Subhashis Banerjee
Joseph Merola

Keywords

Psoriasis, Tyrosine Kinase Inhibitor

Abstract

Abstract not available.

References

1. Spuls PI et al. J Invest Dermatol. 2010;130:933-943.

2. Walsh JA et al. J Am Acad Dermatol. 2013;69:931-937.

3. Duffin KC et al. J Drugs Dermatol. 2017;16:147-153.

4. Gottlieb AB et al. Dermatology. 2019;235:348-354.

5. Merola JF et al. J Invest Dermatol. 2018;138:1955-1961.

6. Watford WT et al. Immunol Rev. 2004;202:139-156.

7. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.

8. Volpe E et al. Nat Immunol. 2008;9:650-657.

9. Geremia A et al. J Exp Med. 2011;208:1127-1133.

10. Tucci M et al. Clin Exp Immunol. 2008;154:247-254.

11. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl10):abstract 11L.

12. Papp K et al. N Engl J Med. 2018;379:1313-1321.

13. Gottlieb AB et al. J Am Acad Dermatol. 2017;77:1178-1180.